Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
3.81 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 28.038 | 43.069 | 59.714 | 54.951 | 82.422 | 25.154 |
| Short Term Investments
| 454.881 | 394.302 | 280.173 | 283.554 | 0 | 0 |
| Cash and Short Term Investments
| 482.919 | 437.371 | 339.887 | 338.505 | 82.422 | 25.154 |
| Net Receivables
| 0 | 7.041 | 4.443 | 0.417 | 0.14 | 0.917 |
| Inventory
| 0 | -7.041 | -4.439 | 0 | 0 | 0 |
| Other Current Assets
| 13.799 | 14.562 | 10.879 | 6.182 | 1.505 | 0.606 |
| Total Current Assets
| 496.718 | 451.933 | 350.77 | 345.104 | 84.067 | 26.677 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 41.735 | 50.078 | 52.839 | 3.619 | 2.836 | 0.26 |
| Goodwill
| 3.736 | 3.736 | 3.736 | 3.736 | 3.736 | 3.736 |
| Intangible Assets
| 0 | 0 | 0 | 8.8 | 8.8 | 8.8 |
| Goodwill and Intangible Assets
| 3.736 | 3.736 | 3.736 | 12.536 | 12.536 | 12.536 |
| Long Term Investments
| 2.681 | 21.213 | 37.495 | 1.32 | 0.243 | -0.046 |
| Tax Assets
| 10.339 | 14.147 | 7.04 | 0.637 | 0.751 | 0.046 |
| Other Non-Current Assets
| 6.818 | -1.797 | 2.627 | 2.339 | 2.224 | 1.525 |
| Total Non-Current Assets
| 65.309 | 87.377 | 103.737 | 20.451 | 18.59 | 14.321 |
| Total Assets
| 562.027 | 539.31 | 454.507 | 365.555 | 102.657 | 40.998 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 14.926 | 11.247 | 11.59 | 8.661 | 4.289 | 3.431 |
| Short Term Debt
| 2.623 | 2.162 | 1.453 | 0.902 | 0.781 | -0.223 |
| Tax Payables
| 0.281 | 0 | 0.971 | 0.41 | 0 | 0 |
| Deferred Revenue
| 0.281 | -2.162 | 0 | 0 | 0 | 0.223 |
| Other Current Liabilities
| 51.537 | 45.4 | 30.901 | 19.038 | 9.827 | 2.777 |
| Total Current Liabilities
| 69.367 | 56.647 | 43.944 | 28.601 | 14.897 | 6.208 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 43.15 | 45.166 | 44.459 | 1.097 | 0 | 0 |
| Deferred Revenue Non-Current
| -0 | 0 | -0.002 | -1.097 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 10.339 | 0.853 | 1.622 | 2.48 | 2.463 | 2.463 |
| Other Non-Current Liabilities
| 1.78 | 2.62 | 0.002 | 1.097 | 1.7 | 0.021 |
| Total Non-Current Liabilities
| 55.269 | 48.639 | 46.081 | 3.577 | 4.163 | 2.484 |
| Total Liabilities
| 124.636 | 105.286 | 90.025 | 32.178 | 19.06 | 8.692 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 141.706 | 59.83 |
| Common Stock
| 0.07 | 0.059 | 0.045 | 0.041 | 0.025 | 2.27 |
| Retained Earnings
| -888.556 | -596.365 | -359.559 | -200.834 | -82.993 | -37.33 |
| Accumulated Other Comprehensive Income/Loss
| 2.194 | -1.353 | -0.125 | 0.036 | -141.706 | -0.056 |
| Other Total Stockholders Equity
| 1,323.576 | 1,031.683 | 724.121 | 534.134 | 159.744 | 0.056 |
| Total Shareholders Equity
| 437.284 | 434.024 | 364.482 | 333.377 | 76.776 | 24.77 |
| Total Equity
| 437.391 | 434.245 | 365.01 | 358.172 | 83.597 | 32.306 |
| Total Liabilities & Shareholders Equity
| 562.027 | 539.31 | 454.507 | 365.555 | 102.657 | 40.998 |